Johanna
Hynninen
Docent, Department of Clinical Medicine
Obstetrics and Gynaecology
Adjunct professor, MD, Gynecologic oncologist
https://sites.utu.fi/ovariancancer/ https://www.deciderproject.eu
Contact
Links
Areas of expertise
gynaecologic oncology
ovarian cancer
Publications
Analysis of single-cell RNA-seq data from ovarian cancer samples before and after chemotherapy links stress-related transcriptional profile with chemotherapy resistance (2020)
bioRxiv
(O2 Muu julkaisu )
HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma (2020)
Acta Oncologica
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Author Correction: Virtual clinical trials identify effective combination therapies in ovarian cancer (2020)
Scientific Reports
(O2 Muu julkaisu )
Extracellular matrix proteins increase invasive growth and chemotherapy resistance of ovarian cancer cells (2020)
Clinical Cancer Research
(O2 Muu julkaisu )
Exploratory Analysis of CA125-MGL and –STn Glycoforms in the Differential Diagnostics of Pelvic Masses (2020)
The Journal of Applied Laboratory Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer (2020)
Clinical Cancer Research
(O2 Muu julkaisu )
The feasibility of [F-18]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study (2020)
EJNMMI Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
American Association for Cancer Research Special Conference on Advances in Ovarian Cancer Research Sep 13-16, 2019 Atlanta, GA, USA Abstracts (2020)
Clinical Cancer Research
(O2 Muu julkaisu )
A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer (2020)
Gynecologic Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors (2020)
Journal of Pathology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))